drugset / Trial / NCT00479986
Effects of Pioglitazone in Type 2 Diabetes Mellitus and Coronary Heart Disease
Phase 4
Completed
92 enrolled
IKFE Institute for Clinical Research and Development
Heidelberg University · collabJohannes Gutenberg University Mainz · collabTakeda · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of the study is to investigate the impact of a 4 week treatment with pioglitazone (in comparison to placebo) on biomarkers for atherosclerosis and cardiovascular risk, as well as the degree of activation of the immune system, when given on top of an anti-diabetic treatment (metformin and/or sulfonylurea drugs) that has already resulted in good glycemic control.
Timeline
- Start
- 2005-06
- Primary completion
- —
- Completion
- 2006-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | — | — |